[Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol].
The pharmacokinetic studies of anticancer drugs still go on after they are out on the market. The therapeutic protocol is then more precise and depends on the dosage results of these drugs. Some examples of dosage adjustment according to their plasmatic level are reported here for high-dose methotrexate infusion and for CDDP infusion over five days. The test dose and the bayesian method (pharmacokinetic population) are used to predict the adapted individualized dosage for each patient.
Favre
R
R
Institut J. Paoli-I. Calmettes, Marseille, France.
Charbit
M
M
Rinaldi
Y
Y
Iliadis
A
A
Cano
J P
JP
Carcassonne
Y
Y
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001499:Bayes Theorem; D002945:Cisplatin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D005069:Evaluation Studies as Topic; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D011358:Product Surveillance, Postmarketing
D000970:Antineoplastic Agents; D002945:Cisplatin; D008727:Methotrexate
La pharmacocinétique dans les études de phase IV pour la prévision du schéma thérapeutique.